• 2025.12.01Others
  Announcement of an Interview Article Related to Our Company in Nature (Digital edition)(138KB)
• 2025.11.26Timely Disclosure
  Announcement of the Initiation of a Phase II Investigator-Initiated Clinical Trial of a PAI-1 Inhibitor (RS5614) Combination Therapy in Chemoradiotherapy and Immune Checkpoint Inhibitor Consolidation Therapy (First-Line Treatment) for Locally Advanced Non-Small Cell Lung Cancer(260KB)
• 2025.11.25Timely Disclosure
  Announcement of completion of patient dosing in the investigator-initiated Phase II clinical trial with the PAI-1 inhibitor RS5614(151KB)
• 2025.11.19Timely Disclosure
  Development of PAI-1 inhibitor RS5614 for veterinary medicines (dogs and cats) has begun(168KB)
• 2025.11.12Financial Statements
  Non-consolidated Financial Results for the Six Months Ended September 30, 2025(Under Japanese GAAP)(203KB)

IR News List